SUDEEPPHRM Q1 FY27 Guidance vs Delivery (SUDEEPPHRM Management Mirror)

Did SUDEEPPHRM's management deliver what it guided? Guidance vs actual performance and tone changes across recent earnings calls, as of the Q1 FY27 (Jun-2026 Qtr) concall.

Sudeep Pharma Ltd (SUDEEPPHRM) Q1FY27 Management Mirror - Jun-2026 Qtr

Consolidated EBITDA Margin Reaffirmed at 37%-38% Long-Term Target; Q1 FY27 Reported at 34.7%

In the Mar'26 Qtr concall, management guided that consolidated EBITDA margins were expected to gradually return to historical levels of 37% to 38% in FY27. In the subsequent Jun'26 Qtr concall, management reaffirmed its long-term target of sustaining consolidated EBITDA margins between 37% and 38%. According to the Quarterly Financial Results for the Jun'26 Qtr (Q1 FY27), the consolidated EBITDA margin was reported as an actual of 34.7%.

5 more themes on the ELITE plan.